Bank Of New York Mellon Corp Sage Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$521 Trillion
Q1 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $8.04 Million - $10.9 Million	249,582 New	249,582 $9.52 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $398,496 - $534,168	12,345 Added 3.51%	364,129 $14.3 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $23,089 - $31,873	-839 Reduced 0.24%	351,784 $11.4 Million
Q1 2022 May 11, 2022	BUY	$30.71 - $45.71 $311,215 - $463,225	10,134 Added 2.96%	352,623 $11.7 Million
Q4 2021 Feb 11, 2022	BUY	$37.06 - $47.11 $3.31 Million - $4.21 Million	89,406 Added 35.33%	342,489 $14.6 Million

Q3 2021 Nov 12, 2021	SELL	$40.26 - $57.37 $868,408 - $1.24 Million	-21,570 Reduced 7.85%	253,083 $11.2 Million
Q2 2021 Aug 11, 2021	BUY	$54.88 - $79.29 $4.14 Million - $5.99 Million	75,491 Added 37.9%	274,653 $15.6 Million
Q1 2021 May 13, 2021	SELL	$70.65 - $96.76 $568,379 - $778,434	-8,045 Reduced 3.88%	199,162 $14.9 Million
Q4 2020 Feb 09, 2021	BUY	$58.41 - $89.06 $204,259 - $311,442	3,497 Added 1.72%	207,207 $17.9 Million
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $131,204 - $199,215	-3,190 Reduced 1.54%	203,710 $12.5 Million
Q2 2020 Aug 12, 2020	SELL	$25.95 - $43.15 $31,607 - $52,556	-1,218 Reduced 0.59%	206,900 $8.6 Million
Q1 2020 May 06, 2020	SELL	$26.15 - $77.24 $8.56 Million - $25.3 Million	-327,485 Reduced 61.14%	208,118 $5.98 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $25.1 Million - $64.7 Million	-417,750 Reduced 43.82%	535,603 $38.7 Million
Q3 2019 Nov 07, 2019	SELL	$140.29 - $189.96 $33.5 Million - $45.3 Million	-238,650 Reduced 20.02%	953,353 $134 Million
Q2 2019 Aug 12, 2019	SELL	$157.85 - $183.09 $42.7 Million - $49.5 Million	-270,622 Reduced 18.5%	1,192,003 $218 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $32.9 Million - $60.4 Million	-368,812 Reduced 20.14%	1,462,625 $233 Million
Q4 2018 Feb 11, 2019	BUY	$81.94 - $139.71 $23.2 Million - $39.5 Million	283,077 Added 18.28%	1,831,437 $175 Million
Q3 2018 Nov 09, 2018	SELL	$138.11 - $169.04 $2.24 Million - $2.74 Million	-16,188 Reduced 1.03%	1,548,360 $0
Q2 2018 Aug 06, 2018	BUY	$140.36 - $175.76 $15.5 Million - $19.4 Million	110,134 Added 7.57%	1,564,548 $245 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $25.3 Million - $32 Million	-166,197 Reduced 10.26%	1,454,414 $234 Million
Q4 2017 Feb 09, 2018	BUY	$60.72 - $167.34 $98.4 Million - $271 Million	1,620,611	1,620,611 $267 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

Vanguard Group Inc Valley Forge, PA

5.75M
Shares

$62 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.48M
Shares

$59.1 Million
1.65% of portfolio
Black Rock Inc. New York, NY

4.89M
Shares

$52.7 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

4.75M
Shares

$51.2 Million
0.02% of portfolio
State Street Corp Boston, MA

4.49M
Shares

$48.5 Million
0.0% of portfolio

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account